Sio Gene Therapies Inc. provided a manufacturing and regulatory update for AXO-Lenti-PD, its clinical-stage gene therapy for Parkinson?s disease. Three GMP batches have successfully completed fill and finish, achieving target titers using the updated suspension-based process Company is on-track to complete final testing of these three batches to support certification of at least one batch for use as clinical trial material by a Qualified Person in Fourth Quarter 2021 Additionally, the Company successfully completed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. regarding the AXO-Lenti-PD clinical development program.